Amedeo Smart

Free Medical Literature Service


 

Amedeo

Colorectal Neoplasms

  Free Subscription

Articles published in
Ann Oncol
    December 2017
  1. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    >> Share

  2. DANIELSEN HE, Hveem TS, Domingo E, Pradhan M, et al
    Prognostic markers for colorectal cancer; estimating ploidy and stroma.
    Ann Oncol. 2017 Dec 27. pii: 4779924. doi: 10.1093.
    >> Share

  3. YAMADA Y, Denda T, Gamoh M, Iwanaga I, et al
    S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial.
    Ann Oncol. 2017 Dec 27. pii: 4779925. doi: 10.1093.
    >> Share

  4. GONG J, Tian J, Lou J, Wang X, et al
    A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267.
    Ann Oncol. 2017 Dec 18. pii: 4756051. doi: 10.1093.
    >> Share

  5. ORDONEZ-ME JM, Walter V, Schottker B, Jenab M, et al
    Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium.
    Ann Oncol. 2017 Dec 13. pii: 4735153. doi: 10.1093.
    >> Share

  6. TABERNERO J, Hozak RR, Yoshino T, Cohn AL, et al
    Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study.
    Ann Oncol. 2017 Dec 7. pii: 4708229. doi: 10.1093.
    >> Share

    November 2017
  7. YOSHINO T, Arnold D, Taniguchi H, Pentheroudakis G, et al
    Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
    Ann Oncol. 2017 Nov 16. doi: 10.1093.
    >> Share

  8. ABAD A, Martinez-Balibrea E, Vieitez JM, Orduna VA, et al
    Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    >> Share

    October 2017
  9. OVERMAN M, Adam L, Raghav K, Wang J, et al
    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    >> Share

  10. TARAZONA N, Cervantes A
    Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    >> Share

  11. SCIALLERO S, Battistuzzi L, Varesco L
    Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer.
    Ann Oncol. 2017;28:2620-2621.
    >> Share

    September 2017
  12. APARICIO T, Bouche O, Taieb J, Maillard E, et al
    Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results.
    Ann Oncol. 2017 Sep 28. doi: 10.1093.
    >> Share

  13. CREMOLINI C, Morano F, Moretto R, Berenato R, et al
    Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    >> Share

  14. GARCIA-FONCILLAS J, Alba E, Aranda E, Diaz-Rubio E, et al
    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    >> Share

  15. SIENA S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, et al
    Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    >> Share

  16. SOBRERO A, Damiani A
    Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.
    Ann Oncol. 2017;28:2043-2044.
    >> Share

  17. WEI Q, Ye Z, Zhong X, Li L, et al
    Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.
    Ann Oncol. 2017;28:2135-2141.
    >> Share

  18. GOEY KKH, Elias SG, van Tinteren H, Lacle MM, et al
    Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Ann Oncol. 2017;28:2128-2134.
    >> Share

    August 2017
  19. NORMANNO N, Esposito Abate R, Lambiase M, Forgione L, et al
    RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Ann Oncol. 2017 Aug 7. doi: 10.1093.
    >> Share

  20. BERGER MD, Stintzing S, Heinemann V, Yang D, et al
    Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    >> Share

  21. WHITE NM, Maher CA
    The potential use of lncRNAs found in the 8q24 region as biomarkers for colon cancer.
    Ann Oncol. 2017;28:1688-1689.
    >> Share

  22. OZAWA T, Matsuyama T, Toiyama Y, Takahashi N, et al
    CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 'gene desert', serve as important prognostic biomarkers in colorectal cancer.
    Ann Oncol. 2017;28:1882-1888.
    >> Share

    July 2017
  23. SANZ-GARCIA E, Argiles G, Elez E, Tabernero J, et al
    BRAF mutant Colorectal Cancer: prognosis, treatment and new perspectives.
    Ann Oncol. 2017 Jul 24. doi: 10.1093.
    >> Share

    May 2017
  24. WILLIS JA, Vilar E
    Refining Prognosis in Early-Stage Colorectal Cancer: One or multiple genes at a time?
    Ann Oncol. 2017 May 26. doi: 10.1093.
    >> Share

  25. SUNAKAWA Y, Tsuji A, Fujii M, Ichikawa W, et al
    No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
    Ann Oncol. 2017 May 5. doi: 10.1093.
    >> Share

  26. DIENSTMANN R, Mason MJ, Sinicrope FA, Phipps AI, et al
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Ann Oncol. 2017;28:1023-1031.
    >> Share

  27. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Ann Oncol. 2017;28:1015-1022.
    >> Share

  28. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
    Ann Oncol. 2017;28:958-968.
    >> Share

    April 2017
  29. ROHR UP, Herrmann P, Ilm K, Zhang H, et al
    Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    >> Share

  30. BOECKX N, Koukakis R, Op de Beeck K, Rolfo C, et al
    Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
    Ann Oncol. 2017 Apr 25. doi: 10.1093.
    >> Share

  31. BONNETAIN F, Borg C, Adams RR, Ajani JA, et al
    How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.
    Ann Oncol. 2017 Apr 18. doi: 10.1093.
    >> Share

  32. VIDAL J, Muinelo L, Dalmases A, Jones F, et al
    Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
    Ann Oncol. 2017 Apr 13. doi: 10.1093.
    >> Share

  33. ARNOLD D, Lueza B, Douillard JY, Peeters M, et al
    Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    >> Share

  34. VIEIRA AR, Abar L, Chan D, Vingeliene S, et al
    Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR Continuous Update Project.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    >> Share

  35. KWAKMAN JJ, Simkens LH, van Rooijen JM, van de Wouw AJ, et al
    Randomised phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
    Ann Oncol. 2017 Apr 5. doi: 10.1093.
    >> Share

  36. FONT R, Espinas JA, Layos L, Martinez Villacampa M, et al
    Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?
    Ann Oncol. 2017;28:831-835.
    >> Share

  37. BUDHATHOKI S, Iwasaki M, Yamaji T, Yamamoto H, et al
    Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population.
    Ann Oncol. 2017;28:818-823.
    >> Share

    March 2017
  38. MA B, King AD, Leung L, Wang K, et al
    Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer - a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
    Ann Oncol. 2017 Mar 30. doi: 10.1093.
    >> Share

  39. ROSPO G, Corti G, Crisafulli G, Novara L, et al
    Tracking colorectal cancer evolution in time and space.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    >> Share

  40. SIRAVEGNA G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al
    Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    >> Share

  41. GRASSELLI J, Elez E, Caratu G, Matito J, et al
    Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    >> Share

  42. FUCHS MA, Yuan C, Sato K, Niedzwiecki D, et al
    Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance).
    Ann Oncol. 2017 Mar 15. doi: 10.1093.
    >> Share

  43. ROMBOUTS AJM, Hugen N, Elferink MAG, Feuth T, et al
    Incidence of second tumors after treatment with or without radiation for rectal cancer.
    Ann Oncol. 2017;28:535-540.
    >> Share

    February 2017
  44. PILATI C, Taieb J, Balogoun R, Marisa L, et al
    CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Ann Oncol. 2017 Feb 27. doi: 10.1093.
    >> Share

  45. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    >> Share

  46. LOTE H, Spiteri I, Ermini L, Vatsiou A, et al
    Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    >> Share

  47. SANTINI D, Vincenzi B, Addeo R, Garufi C, et al
    Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    >> Share

  48. DIENSTMANN R, Mason MJ, Sinicrope FA, Phipps AI, et al
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    >> Share

  49. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    >> Share

  50. PATEL UB, Brown G, Machado I, Santos-Cores J, et al
    MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
    Ann Oncol. 2017;28:344-353.
    >> Share

  51. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    >> Share

    January 2017
  52. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and Prognostication in Stage III Colon Cancer: Future Perspectives for Adjuvant Therapy.
    Ann Oncol. 2017 Jan 27. pii: mdx030. doi: 10.1093.
    >> Share

    December 2016
  53. TAIEB J, Balogoun R, Le Malicot K, Tabernero J, et al
    Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Ann Oncol. 2016 Dec 28. pii: mdw687. doi: 10.1093.
    >> Share

  54. SCHUURHUIZEN CS, Braamse AM, Konings IR, Sprangers MA, et al
    Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review.
    Ann Oncol. 2016 Dec 19. pii: mdw617. doi: 10.1093.
    >> Share

  55. SELIGMANN JF, Fisher D, Smith CG, Richman SD, et al
    Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials.
    Ann Oncol. 2016.
    >> Share

    November 2016
  56. PIETRANTONIO F, Miceli R, Rimassa L, Lonardi S, et al
    Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
    Ann Oncol. 2016.
    >> Share

  57. SWETS M, Breugom AJ, Gelderblom H, van de Velde CJ, et al
    Should rectal cancer located 10-15cm from the anal verge be defined as colon cancer.
    Ann Oncol. 2016.
    >> Share

    October 2016
  58. QUIDDE J, Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al
    Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
    Ann Oncol. 2016.
    >> Share

  59. STELLOO E, Jansen AM, Osse EM, Nout RA, et al
    Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
    Ann Oncol. 2016.
    >> Share

  60. MOORE M, Gill S, Asmis T, Berry S, et al
    Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
    Ann Oncol. 2016.
    >> Share

  61. DEENEN MJ, Meulendijks D
    Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    >> Share

    September 2016

  62. appendix 5: Metastatic colorectal cancer (2): eUpdate published online August 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    >> Share


  63. appendix 4: Metastatic colorectal cancer (1): eUpdate published online September 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    >> Share

    August 2016
  64. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2016.
    >> Share

  65. IMAOKA H, Toiyama Y, Fujikawa H, Hiro J, et al
    Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
    Ann Oncol. 2016.
    >> Share

    July 2016
  66. VARDY JL, Dhillon HM, Pond GR, Renton C, et al
    Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study.
    Ann Oncol. 2016.
    >> Share

  67. MEI Z, Duan C, Li C, Cui L, et al
    Prognostic role of tumor PIK3CAmutation in colorectal cancer: a systematic review and meta-analysis.
    Ann Oncol. 2016.
    >> Share

  68. VAN CUTSEM E, Cervantes A, Adam R, Sobrero A, et al
    ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    >> Share

    June 2016
  69. MODEST DP, Ricard I, Heinemann V, Hegewisch-Becker S, et al
    Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants - pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Ann Oncol. 2016.
    >> Share

  70. SOBRERO A
    A tribute to biologics in advanced colorectal cancer treatment.
    Ann Oncol. 2016.
    >> Share

    May 2016
  71. MICHL M, Stintzing S, Fischer von Weikersthal L, Decker T, et al
    CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Ann Oncol. 2016.
    >> Share

  72. REN HG, Luu HN, Cai H, Xiang YB, et al
    Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis.
    Ann Oncol. 2016.
    >> Share

  73. LUO HY, Xu RH
    Reply to "Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients" by C. Cremolini et al.
    Ann Oncol. 2016.
    >> Share

  74. YAMAZAKI K, Nagase M, Tamagawa H, Ueda S, et al
    Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
    Ann Oncol. 2016.
    >> Share

  75. CREMOLINI C, Moretto R, Masi G, Falcone A, et al
    Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients.
    Ann Oncol. 2016.
    >> Share

  76. SARTORE-BIANCHI A, Loupakis F, Argiles G, Prager GW, et al
    Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the lab.
    Ann Oncol. 2016.
    >> Share

    February 2016
  77. ROSATI G, Ambrosini G, Barni S, Andreoni B, et al
    A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma.
    Ann Oncol. 2016;27:274-80.
    >> Share

    December 2014
  78. SCHOFFSKI P, Besse B, Gauler T, de Jonge MJ, et al
    Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell l
    Ann Oncol. 2014.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016